

The effects of grape seed extract intake on health

Submission date 25/02/2022	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 03/03/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 18/12/2023	Condition category Other	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Grape seeds (*Vitis vinifera*) are a rich source of oligomeric proanthocyanidins (PAC), a class of polyphenols with potential health-promoting effects. However, these polyphenols are poorly absorbed and reach the large intestine where they are transformed by bacteria. These metabolic products could be responsible for the beneficial effects. The aims of this study are: i) to identify and quantify the main components/metabolites of grape seed in the urine of healthy volunteers; ii) to evaluate the activation of genes involved in the antioxidant and inflammatory response. The results will improve our understanding of the metabolism of PAC and the potential health effects of these components and their metabolic products on the antioxidant response.

Who can participate?

Healthy men and women aged 18-40 years with a normal weight (body mass index 18-25 kg/m²)

What does the study involve?

Participants will be randomly allocated to take two capsules per day of oligomeric proanthocyanidin or placebo (dummy capsules) for 7 days. Blood and urine samples will be collected at the start of the study and after 7 days. After a 1-week break, participants swap to the opposite capsules for 7 days and urine and blood samples are collected again. Body measurements and tests will be carried out at the start of the study.

What are the possible benefits and risks of participating?

Oligomeric proanthocyanidin (PAC) may be broken down and activate the body's defence mechanisms against oxidative stress and inflammation. There are no expected risks.

Where is the study run from?

1. Department of Pharmaceutical Sciences, DiSFARM- Università degli Studi di Milano (Italy)
2. Department of Food, Environmental and Nutritional Sciences, DeFENS-Università degli Studi di Milano (Italy)

When is the study starting and how long is it expected to run for?

September 2021 to November 2022

Who is funding the study?
Distillerie Bonollo S.p.A, Formigine (Italy)

Who is the main contact?
1. Prof. Giancarlo Aldini, giancarlo.aldini@unimi.it
2. Dr Cristian Del Bo', cristian.delbo@unimi.it

Contact information

Type(s)

Principal investigator

Contact name

Prof Giancarlo Aldini

ORCID ID

<https://orcid.org/0000-0002-2355-6744>

Contact details

University of Milan-Department of Pharmaceutical Sciences
Milano
Italy
20133
+39 (0)250319296
giancarlo.aldini@unimi.it

Type(s)

Scientific

Contact name

Dr Cristian Del Bo'

ORCID ID

<https://orcid.org/0000-0001-7562-377X>

Contact details

Via Luigi Mangiagalli 25
Milan
Italy
20133
+39 (0)250316730
cristian.delbo@unimi.it

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

Protocol serial number

Nil known

Study information

Scientific Title

Metabolic profile of a standardized extract of oligomeric procyanidins (PACs) from *Vitis vinifera* seeds in the urine and plasma of healthy volunteers and application of omic sciences for a better understanding of the biological action

Acronym

METAPAC

Study objectives

This pilot study aims to test the hypothesis that oligomeric procyanidins from a standardized *Vitis vinifera* seed extract are absorbed and metabolized, and can induce the activation of genes involved in the antioxidants and anti-inflammatory response.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 15/09/2021, the Ethics Committee of the University of Milan (Via Festa del Perdono 7, 20122, Milano, Italia; +39 (0)2 503.12667; comitato.etico@unimi.it), ref: 94/21

Study design

Randomized controlled crossover intervention study

Primary study design

Interventional

Study type(s)

Prevention

Health condition(s) or problem(s) studied

Metabolism and biological activity of oligomeric procyanidins

Interventions

Ten healthy volunteers will be enrolled and randomized by block randomization to consume two capsules per day (one in the morning and one in the evening) of *Vitis vinifera* extract (300 mg oligomeric procyanidins) or placebo (dicalcium phosphate, cellulose, silicon dioxide, magnesium salts of fatty acids, titanium dioxide). Each treatment will be 7 days and separated by at least a 1-week wash-out period.

Intervention Type

Supplement

Primary outcome(s)

Urinary excretion of oligomeric proanthocyanidin-derived human phenyl- γ -valerolactone metabolite from *Vitis vinifera*, measured using high-resolution mass spectrometry techniques at baseline and at 1, 2, 4, 6, 10, 12, 14, 24 and 48 hours after the intervention and reported as absolute urinary concentration (nmoles/ml)

Key secondary outcome(s)

1. Lipidomic, proteomic and metabolomic status measured by using omics approaches (e.g., proteomic, lipidomic, metabolomic) in the buffy coat at baseline, after 2 hours, and 7 days post-intervention. Values will be reported semi-quantitatively as fold-change.
2. Levels of DNA damage in the buffy coat measured by comet assay at baseline, after 2 hours and 7 days post intervention
3. Levels of 8-hydroxy-2'-deoxyguanosine (8-OHdG) in plasma and urine measured using ELISA kit at baseline, after 2 hours and 7 days post intervention

Completion date

30/11/2022

Eligibility**Key inclusion criteria**

1. Women and men
2. Aged 18-40 years
3. BMI 18-25 kg/m²
4. Healthy
5. No smokers

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

40 years

Sex

All

Total final enrolment

10

Key exclusion criteria

1. Smokers
2. Allergy to grape
3. Gastrointestinal disorder
4. Liver and renal disease
5. Antibiotic treatment
5. Use of supplements

Date of first enrolment

10/03/2022

Date of final enrolment

30/03/2022

Locations

Countries of recruitment

Italy

Study participating centre

University of Milan - DISFARM-DeFENS

Via Luigi Mangiagalli 25

Milano

Italy

20133

Sponsor information

Organisation

University of Milan

ROR

<https://ror.org/00wjc7c48>

Funder(s)

Funder type

Industry

Funder Name

Distillerie Bonollo Umberto S.p.A

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are/will be available upon request from:

1. Prof. Giancarlo Aldini (giancarlo.aldini@unimi.it)

2. Dr Cristian Del Bo' (cristian.delbo@unimi.it)

Data are anonymous and consent was obtained from participants.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		07/12/2023	18/12/2023	Yes	No